Top Markets
#1 MowCat MowCat +806.41%
#2 龙虾 (Lobster) 龙虾 (Lobster) +81.35%
#3 SODAX SODAX +49.28%
#4 Cortex Cortex +28.41%
#5 Pons Pons +20.34%
#6 Magma Finance Magma Finance +18.46%
#7 Akedo Akedo +16.59%
#8 MarsCoin MarsCoin +14.23%
#9 OpenEden OpenEden +13.27%
#10 APEX APEX +12.08%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
Rangering i aksjer #7186
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Aksjekurs
$38.45
Markedsverdi
$1.68B
Endring (1 dag)
-1.24%
Endring (1 år)
50.36%
Land
KR
Handel D&D Pharmatech (347850)

Kategori

Healthcare
EPS for D&D Pharmatech (347850)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til D&D Pharmatech er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for D&D Pharmatech fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH